These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 12820313)
41. Accuracy of four fecal assays in the diagnosis of colitis. Schoepfer AM; Trummler M; Seeholzer P; Criblez DH; Seibold F Dis Colon Rectum; 2007 Oct; 50(10):1697-706. PubMed ID: 17762964 [TBL] [Abstract][Full Text] [Related]
42. Tumor M2-pyruvate kinase in lung cancer patients: immunohistochemical detection and disease monitoring. Schneider J; Neu K; Grimm H; Velcovsky HG; Weisse G; Eigenbrodt E Anticancer Res; 2002; 22(1A):311-8. PubMed ID: 12017309 [TBL] [Abstract][Full Text] [Related]
43. [Calprotectin levels in patients with idiopathic inflammatory bowel disease comparison of two commercial tests]. Malícková K; Janatková I; Bortlík M; Komárek V; Lukás M Epidemiol Mikrobiol Imunol; 2008 Nov; 57(4):147-53. PubMed ID: 19069028 [TBL] [Abstract][Full Text] [Related]
44. Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study. Shastri YM; Loitsch S; Hoepffner N; Povse N; Hanisch E; Rösch W; Mössner J; Stein JM Am J Gastroenterol; 2008 Jun; 103(6):1496-504. PubMed ID: 18510609 [TBL] [Abstract][Full Text] [Related]
45. Value of tumor M2-PK in thyroid carcinoma: a pilot study. Bena-Boupda NF; Rezai SS; Klett R; Eigenbrodt E; Bauer R Anticancer Res; 2003; 23(6D):5237-40. PubMed ID: 14981996 [TBL] [Abstract][Full Text] [Related]
46. The Diagnostic Accuracy of the M2 Pyruvate Kinase Quick Stool Test--A Rapid Office Based Assay Test for the Detection of Colorectal Cancer. Sithambaram S; Hilmi I; Goh KL PLoS One; 2015; 10(7):e0131616. PubMed ID: 26158845 [TBL] [Abstract][Full Text] [Related]
47. Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma. Oremek GM; Sapoutzis N; Kramer W; Bickeböller R; Jonas D Anticancer Res; 2000; 20(6D):5095-8. PubMed ID: 11326675 [TBL] [Abstract][Full Text] [Related]
48. Plasma levels of HER-2/neu, tumor type M2 pyruvate kinase and its tyrosine-phosphorylated metabolite in advanced breast cancer. Lüftner D; Mazurek S; Henschke P; Mesterharm J; Schildhauer S; Geppert R; Wernecke KD; Possinger K Anticancer Res; 2003; 23(2A):991-7. PubMed ID: 12820337 [TBL] [Abstract][Full Text] [Related]
50. Quantification of tumor type M2 pyruvate kinase (Tu M2-PK) in human carcinomas. Eigenbrodt E; Basenau D; Holthusen S; Mazurek S; Fischer G Anticancer Res; 1997; 17(4B):3153-6. PubMed ID: 9329624 [TBL] [Abstract][Full Text] [Related]
51. Fecal Adnab-9 binding as a risk marker for colorectal neoplasia. Yuan M; Xhang X; Leu Y; Xu Y; Ullah N; Lawson M; Tobi M Cancer Lett; 2006 Apr; 235(1):48-52. PubMed ID: 15893419 [TBL] [Abstract][Full Text] [Related]
52. Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK. Tonus C; Neupert G; Sellinger M World J Gastroenterol; 2006 Nov; 12(43):7007-11. PubMed ID: 17109496 [TBL] [Abstract][Full Text] [Related]
53. [Usefulness of plasma tumor M2-pyruvate kinase in the diagnosis of gastrointestinal cancer]. Kim CW; Kim JI; Park SH; Han JY; Kim JK; Chung KW; Sun HS Korean J Gastroenterol; 2003 Nov; 42(5):387-93. PubMed ID: 14646575 [TBL] [Abstract][Full Text] [Related]
54. Tumor marker M2-pyruvate-kinase in differential diagnosis of chronic pancreatitis and pancreatic cancer. Novotný I; Dítĕ P; Dastych M; Záková A; Trna J; Novotná H; Nechutová H Hepatogastroenterology; 2008; 55(85):1475-7. PubMed ID: 18795715 [TBL] [Abstract][Full Text] [Related]
55. Diagnosis of gastric malignancy using gastric juice alpha1-antitrypsin. Hsu PI; Chen CH; Hsiao M; Wu DC; Lin CY; Lai KH; Lu PJ Cancer Epidemiol Biomarkers Prev; 2010 Feb; 19(2):405-11. PubMed ID: 20086110 [TBL] [Abstract][Full Text] [Related]
57. Diagnostic value of tumor M2-pyruvate kinase in neuroendocrine tumors. A comparative study with chromogranin A. Pezzilli R; Migliori M; Morselli-Labate AM; Campana D; Ventrucci M; Tomassetti P; Corinaldesi R Anticancer Res; 2003; 23(3C):2969-72. PubMed ID: 12926146 [TBL] [Abstract][Full Text] [Related]
58. A new approach to fecal occult blood testing based on the detection of haptoglobin. Xing PX; Young GP; Ho D; Sinatra MA; Hoj PB; McKenzie IF Cancer; 1996 Jul; 78(1):48-56. PubMed ID: 8646726 [TBL] [Abstract][Full Text] [Related]
59. Evaluation of calgranulin B in stools from the patients with colorectal cancer. Yoo BC; Shin YK; Lim SB; Hong SH; Jeong SY; Park JG Dis Colon Rectum; 2008 Nov; 51(11):1703-9. PubMed ID: 18584251 [TBL] [Abstract][Full Text] [Related]
60. Detection of gastric cancer and premalignant lesions by novel marker glycoprotein 87 using monoclonal antibody Adnab-9. Qiao SX; Yuan M; Liu YL; Lin XS; Zhang XP; Tobi M Cancer Epidemiol Biomarkers Prev; 2003 Oct; 12(10):1095-9. PubMed ID: 14578149 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]